Dirlotapide

From Wikipedia, the free encyclopedia - View original article

Dirlotapide
Dirlotapide structure.svg
Systematic (IUPAC) name
1-Methyl-N-[(1S)-2-(methyl-(phenylmethyl)amino)-2-oxo-1-phenylethyl]-5-[​[oxo-[2-[4-(trifluoromethyl)phenyl]phenyl]methyl]amino]-2-indolecarboxamide
Clinical data
AHFS/Drugs.comInternational Drug Names
Legal status?
Identifiers
CAS number481658-94-0 YesY
ATCvet codeQA08AB91
PubChemCID 9917862
ChemSpider8093509 YesY
UNII578H0RMP25 YesY
KEGGD03867 YesY
ChEMBLCHEMBL410414 YesY
Chemical data
FormulaC40H33F3N4O3 
Mol. mass674.71 g/mol
 YesY (what is this?)  (verify)
 
Jump to: navigation, search
Dirlotapide
Dirlotapide structure.svg
Systematic (IUPAC) name
1-Methyl-N-[(1S)-2-(methyl-(phenylmethyl)amino)-2-oxo-1-phenylethyl]-5-[​[oxo-[2-[4-(trifluoromethyl)phenyl]phenyl]methyl]amino]-2-indolecarboxamide
Clinical data
AHFS/Drugs.comInternational Drug Names
Legal status?
Identifiers
CAS number481658-94-0 YesY
ATCvet codeQA08AB91
PubChemCID 9917862
ChemSpider8093509 YesY
UNII578H0RMP25 YesY
KEGGD03867 YesY
ChEMBLCHEMBL410414 YesY
Chemical data
FormulaC40H33F3N4O3 
Mol. mass674.71 g/mol
 YesY (what is this?)  (verify)

Dirlotapide is a drug used to treat obesity in dogs. It is manufactured by Pfizer and marketed as Slentrol.

It works as a selective microsomal triglyceride transfer protein (MTTP) inhibitor. This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption. It also elicits a satiety signal from lipid-filled cells lining the intestine.

It is supplied as an oral solution. It is not intended for use in humans, cats, or parrots.

On January 5, 2007, the U.S. Food and Drug Administration (FDA) approved Slentrol, the first time the FDA has approved a drug for obese dogs.[1]

Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It should be used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination. Allergic reaction to the medication may include, facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma. Contact your veterinarian if you observe any of these signs. The dose of dirlotapide will need to be recalculated each month, based on your dog's weight.

Canine patient information sheet http://www.drsfostersmith.com/Rx_Info_Sheets/rx_dirlotapide.pdf

References[edit]

  1. ^ "FDA approves 1st drug for obese dogs". Yahoo. Archived from the original on January 8, 2007. Retrieved 2007-01-06. 

External links[edit]